SCHEMBL343088

SCHEMBL343088

O=C(O)CNC1CCCCO1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.33
HPGD P15428 4/20 0.33
HTT P42858 1/20 0.33
SLC6A3 Q01959 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
EGLN1 Q9GZT9 2/20 0.31
HIF1AN Q9NWT6 2/20 0.31
BBOX1 O75936 1/20 0.31
ASPH Q12797 1/20 0.31
KDM8 Q8N371 1/20 0.31
TP53 P04637 2/20 0.31
ALOX12 P18054 1/20 0.31
OGFOD1 Q8N543 1/20 0.31
EGLN2 Q96KS0 1/20 0.31
EGLN3 Q9H6Z9 1/20 0.31
RXRA P19793 1/20 0.30
RXRB P28702 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901643 1.00 ALDH1A1 (0.33) ALDH1A1HPGDHTTSLC6A3KDM4E
SCHEMBL7335663 0.94 ALDH1A1 (0.38) ALDH1A1HPGDHTTKDM4ELMNA
SCHEMBL7347720 0.94 ALDH1A1 (0.38) ALDH1A1HPGDHTTKDM4ELMNA
SCHEMBL30918323 0.80 EPHX2 (0.42) ALDH1A1HPGDSLC6A3LMNAMEN1
SCHEMBL6687035 0.77
SCHEMBL377817 0.74
SCHEMBL175364 0.74 GRIK1 (0.36) SLC6A3
SCHEMBL1512978 0.74 GRIK1 (0.36) SLC6A3
SCHEMBL3758731 0.74 HPGD (0.35) ALDH1A1HPGDHTTSLC6A3KDM4E
Acetic Acid SCHEMBL2995772 0.73 DPP4 (0.33) ALDH1A1HPGDHTTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP claimed
WO-2024110477-A2 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 WO claimed
EP-2518080-B1 Antibiotic peptides AMP THERAPEUTICS GMBH (DE) 2016-05-18 EP claimed
US-20150315241-A1 Antibiotic Peptides AMP-THERAPEUTICS GMBH (DE) 2015-11-05 US claimed
US-9060513-B2 Antibiotic peptides AMP-THERAPEUTICS GMBH (DE) 2015-06-23 US claimed
EP-2170928-B1 ANTIBIOTIC PEPTIDES AMP THERAPEUTICS GMBH (DE) 2013-07-03 EP claimed
EP-2518080-A2 Antibiotic peptides AMP-Therapeutics GmbH & Co. KG (DE) 2012-10-31 EP claimed
US-20100222268-A1 ANTIBIOTIC PEPTIDES AMP-THERAPEUTICS GMBH & CO. KG 2010-09-02 US claimed
EP-2170928-A1 ANTIBIOTIC PEPTIDES AMP-Therapeutics GmbH & Co. KG (DE) 2010-04-07 EP claimed
WO-2009013262-A1 ANTIBIOTIC PEPTIDES UNIVERSITÄT LEIPZIG (DE) 2009-01-29 WO claimed
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP disclosed
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-07-04 US disclosed
CN-108697756-B HER2 peptide reagents and methods 密歇根大学董事会 2022-05-27 CN disclosed
CN-114269367-A Therapeutic peptides 科巴公司 2022-04-01 CN disclosed
CN-113518784-A Therapeutic peptides 科巴公司 2021-10-19 CN disclosed
WO-2006014361-A1 INHIBITORS OF IAP GENENTECH, INC. (US) 2006-02-09 WO disclosed
US-20060014700-A1 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies GENENTECH, INC. (US) 2006-01-19 US disclosed
US-5932567-A Thrombin inhibitors BASF AKTIENGESELLSCHAFT (DE) 1999-08-03 US disclosed
EP-0809651-A1 THROMBIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1997-12-03 EP disclosed
WO-1996024609-A1 THROMBIN INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 1996-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218014-A1 SYNTHESIS OF A CYCLIC PEPTIDE VIP, QPCT, PTMS ALDH1A1 4766/4885HPGD 1250/4885HTT 3041/4885
US-20060014700-A1 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies BIRC5, BIRC2, XIAP ALDH1A1 2930/4885HPGD 3144/4885HTT 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.